News | Computer-Aided Detection Software | April 04, 2019

Company’s latest deep-learning cancer detection software solution recently launched in U.S.

iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium

April 4, 2019 — iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast tomosynthesis (DBT), ProFound AI, as well as its PowerLook Density Assessment software, during the 2019 Society of Breast Imaging (SBI) Annual Symposium, April 4-7, in Hollywood, Fla.

ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT. The technology delivers critical benefits to radiologists, their facilities and patients through the improvement of cancer detection rates by an average of 8 percent and a reduction in the rate of unnecessary patient recalls by an average of 7 percent. It is designed to detect malignant soft-tissue densities and calcifications, and provides radiologists with the certainty of finding lesion and case scores. Since its U.S. launch in December 2018, ProFound AI has been adopted by a significant number of high-profile hospitals and imaging centers in all major geographic areas of the country, according to iCAD.

“Enhanced breast cancer detection remains a critical healthcare initiative, as evidenced by the recently proposed regulations from the U.S. Food and Drug Administration (FDA) requiring breast density reporting,” said Stacey Stevens, president of iCAD.  “The new proposed regulations would enhance FDA’s ability to enforce mammography facilities’ compliance with breast density reporting standards.” She added that PowerLook Density Assessment is designed to standardize the assessment of fibroglandular breast density in 2-D and 3-D mammography, which could play an important role in healthcare facilities’ ability to adhere to the new proposed FDA regulations.

For more information: www.icadmed.com


Related Content

Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
Subscribe Now